A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. (1/94)

 (+info)

Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. (2/94)

 (+info)

Innate immune responses to human rotavirus in the neonatal gnotobiotic piglet disease model. (3/94)

 (+info)

Recent advances in Ebolavirus vaccine development. (4/94)

Ebolavirus is a highly infectious pathogen with a case fatality rate as high as 90%. Currently there is a lack of licensed Ebolavirus vaccines as well as pre- and post-exposure treatments. Recent increases in the frequency of natural human Ebolavirus infections and its potential use as a bioterrorism agent makes vaccine development a priority for many nations. Significant progress has been made in understanding the pathogenesis of Ebolavirus infection and several promising vaccine candidates were shown to be successful in protecting NHPs against lethal infection. These include replication-deficient adenovirus vectors, replication-competent VSV, HPIV-3 vectors and virus-like particle preparations. Recent advances in the generation of effective post-exposure immunization strategies highlight the possibility of developing a single dose vaccine that will confer full protection in humans following Ebolavirus exposure. Post-exposure protection is particularly important in outbreak and biodefense settings, as well as clinical and laboratory settings in the case of accidental exposure.  (+info)

Formulation of microneedles coated with influenza virus-like particle vaccine. (5/94)

 (+info)

Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. (6/94)

 (+info)

Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. (7/94)

 (+info)

Conference Scene: Summary report from EAACI: London 2010. (8/94)

 (+info)